Solid Biosciences to raise $240 mln in private funding, shares rise

Shares of genetic-muscle disorder drug developer Solid Biosciences SLDB.O rise 14.26% to $6.43 premarket

 Company says it will raise about $240 mln in a private funding round to support research and operations

 Says it will sell nearly 15 mln shares at $5.61 each and issue warrants for up to 28 mln more shares

 Investors in the round include Perceptive Advisors, Bain Capital Life Sciences, RA Capital and others - SLDB

  Company says proceeds will fund gene therapy programs for Duchenne muscular dystrophy, a muscle-wasting disease

Shares up 41% in 2025